The global cancer crisis: a review of growing burden, deepening inequality and initiatives for prevention and early detection

Cancer constitutes one of the most urgent global health crises, with over 20 million new cases diagnosed annually worldwide, claiming 10 million lives. This devastating burden disproportionately affects vulnerable populations: 75% of cancer deaths occur in low- and middle-income countries despite these regions having lower reported incidence rates. Lung cancer leads the global toll, representing 12% of all cases but 19% of deaths, followed by breast cancer (12% of cases) and colorectal cancer (9.6%). A stark geographical inequity defines the cancer landscape-while wealthy regions such as North America, Northern Europe and Australia report the highest incidence rates, Africa and Latin America suffer the highest mortality rates. This disparity will intensify dramatically: cancer deaths in low-income countries are projected to surge 155% compared to just 56% in high-income nations by 2050. The financial devastation compounds this crisis, with 56% of patients worldwide facing catastrophic health expenditures extending beyond medical costs to include lost income and reduced productivity. Economic burden varies starkly by wealth: 75% of patients in low-income countries experience financial catastrophe versus 58% in middle-income countries and 26% in high-income nations. However, cancer prevention offers unprecedented opportunities to transform this crisis through interventions we already possess. From largely preventable infectious cancers like stomach and cervical malignancies, to lifestyle-driven epidemics including lung and colorectal cancers, to complex multifactorial diseases like breast cancer. Evidence-based prevention strategies can dramatically reduce suffering while generating massive healthcare savings. Emerging genetic technologies amplify this potential: universal genetic testing and pharmacogenomics now enable identification of high-risk individuals before disease develops, allowing targeted prevention while optimising treatments based on individual genetic profiles. Cancer prevention represents not merely a health opportunity but an economic imperative. The primary barrier is no longer scientific understanding but systematic implementation. Governments, policymakers, insurance companies and the public urgently need clearer evidence and education demonstrating proven successes to motivate decisive action toward creating healthier populations and reducing cancer burdens worldwide.

Authors

Institutions

Publication Details

Journal
ecancermedicalscience
Published
2026-02-03
DOI
https://doi.org/10.3332/ecancer.2026.2071
Primary Topic
Global Cancer Incidence and Screening
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The global cancer crisis: a review of growing burden, deepening inequality and initiatives for prevention and early detection

Bernard Esquivel, Soon Thye Lim, Felipe J. F Coimbra, Odysseas Zoras et al.
ecancermedicalscience
Global Cancer Incidence and Screening
article

The global cancer crisis: a review of growing burden, deepening inequality and initiatives for prevention and early detection

Bernard Esquivel, Soon Thye Lim, Felipe J. F Coimbra, Odysseas Zoras, John E. Niederhuber, King-David Terna Yawe, Ning Liao, Judy E. Garber, Jin He, Funmi Olopade, Mansoor N. Saleh, Yuko Kitagawa, Oscar Arrieta, Domenica Lorusso, Victor H F Lee, David C Whiteman, V Suzanne Kimberg, Raymond Sawaya, Miriam Mutebi, Geerard L Beets, Piotr Rutkowski, Riccardo A Audisio, William M Sanchez, Charles M Balch, Cornelia Ulrich, Allison W Kurian, Jie He, Carlos S Vallejos, Eduardo Cazap, Hope S Rugo, Tony S K Mok, Jorge E Gallardo, Denis S C Lam, Ronald M K Lam, William J Gradishar, Gerhardt Attard, YiLong Wu, Jeffrey N Weitzel, Ashraf Saad Zaghloul, Banu K Arun, N D Perrier, Edward S F Liu, Xianqun Fan, Isabel T Rubio, Chandrakanth Are, Alessandro Gronchi, John W. Thompson, Hector Martinez Said, Alexander M M Eggermont, Jeffrey E Gershenwald, Louis W C Chow, Paul A Bunn, Nayef Awad Al Zahrani, Gerald Tumusiime, Rui-Hua Xu, I Soerjomataram, J Vignat
article en

Abstract

Cancer constitutes one of the most urgent global health crises, with over 20 million new cases diagnosed annually worldwide, claiming 10 million lives. This devastating burden disproportionately affects vulnerable populations: 75% of cancer deaths occur in low- and middle-income countries despite these regions having lower reported incidence rates. Lung cancer leads the global toll, representing 12% of all cases but 19% of deaths, followed by breast cancer (12% of cases) and colorectal cancer (9.6%). A stark geographical inequity defines the cancer landscape-while wealthy regions such as North America, Northern Europe and Australia report the highest incidence rates, Africa and Latin America suffer the highest mortality rates. This disparity will intensify dramatically: cancer deaths in low-income countries are projected to surge 155% compared to just 56% in high-income nations by 2050. The financial devastation compounds this crisis, with 56% of patients worldwide facing catastrophic health expenditures extending beyond medical costs to include lost income and reduced productivity. Economic burden varies starkly by wealth: 75% of patients in low-income countries experience financial catastrophe versus 58% in middle-income countries and 26% in high-income nations. However, cancer prevention offers unprecedented opportunities to transform this crisis through interventions we already possess. From largely preventable infectious cancers like stomach and cervical malignancies, to lifestyle-driven epidemics including lung and colorectal cancers, to complex multifactorial diseases like breast cancer. Evidence-based prevention strategies can dramatically reduce suffering while generating massive healthcare savings. Emerging genetic technologies amplify this potential: universal genetic testing and pharmacogenomics now enable identification of high-risk individuals before disease develops, allowing targeted prevention while optimising treatments based on individual genetic profiles. Cancer prevention represents not merely a health opportunity but an economic imperative. The primary barrier is no longer scientific understanding but systematic implementation. Governments, policymakers, insurance companies and the public urgently need clearer evidence and education demonstrating proven successes to motivate decisive action toward creating healthier populations and reducing cancer burdens worldwide.

ecancermedicalscienceVol. 20
City Of Hope National Medical Center (US), Tokai University (JP), Department of Health (CN), Humanitas University (IT), The University of Texas MD Anderson Cancer Center (US), Johns Hopkins University (US), Sun Yat-sen University (CN), Chinese University of Hong Kong (HK), Breast Cancer Research Foundation (US), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Keio University (JP), Fundación Chile (CL), QIMR Berghofer Medical Research Institute (AU), Society for Family Health Nigeria (NG), Aga Khan University Hospital Nairobi (KE), Maastricht University Medical Centre (NL), University College Hospital, Ibadan (NG), Sahlgrenska University Hospital (SE), Caritas Medical Centre (CN), AC Camargo Hospital (BR), Maastricht University (NL), University of Chicago (US), Military University Nueva Granada (CO), Unimed Medical Institute (CN), Shanghai Ninth People's Hospital (CN), The University of Kansas Cancer Center (US), Facultad Latinoamericana de Ciencias Sociales Sede Argentina (AR), Aga Khan University Nairobi (KE), City of Hope (US), Military University (RU), Dana-Farber Cancer Institute (US), Melanoma Institute Australia (AU), National Institute of Oncology (HU), Tumour Institute of Tuscany (IT), Palo Alto Institute (US), Princess Máxima Center (NL), Forum Solidaridad Perú (PE), University of Colorado Cancer Center (US), National Cancer Centre Singapore (SG), Vietnam National Children's Hospital (VN), National Water Research Center (EG), Sun Yat-sen University Cancer Center (CN), CRUK Lung Cancer Centre of Excellence (GB), AXYS Technologies (Canada) (CA), Metropolitan Hospital (GR), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), Guangdong Provincial People's Hospital (CN), Instituto Nacional de Cancerología (MX), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Children Cancer Hospital (EG), Centre international de recherche sur le cancer (FR), National Guard Health Affairs (SA), The University of Texas Medical Branch at Galveston (US), University of Nebraska Medical Center (US), Ludwig-Maximilians-Universität München (DE), University of Hong Kong (HK), University of Colorado Denver (US), Uganda Christian University (UG), Stanford University (US), American University of Beirut (LB)
No poverty
Openalex Percentile: Top 67%
Global Cancer Incidence and Screening
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.